Earendil Labs
- Health & Biotech
- Wilmington, Delaware, US
- Founded 2025
- Private
- earendil.bio
AI-driven biotech developing antibody therapies, including bispecifics, for autoimmune disease and cancer; affiliated with Helixon Therapeutics.
$787MEquity raised in 2025–20262025 — · 2026 $787M · 1 equity round
$787MEquity raised, all time1 equity round sourced so far
—Latest valuationnot disclosed
Rounds over time log-scaled amounts
Funding history 1 round · 2 sources
Earlier rounds not yet sourced. Earendil Labs was founded in 2025 and raised before 20 Mar 2026; only the rounds below are sourced so far, so its all-time equity total understates its history.
- Financing roundsAmount$787MPost-money—✓ Confirmed
- Earlier rounds not yet sourced
Investors 7
- Biotech Development Fund
- Dimension
- DST Global
- INCE Capital
- Luminous Ventures
- Miracle Capital
- Sanofi
Highlighted investors led at least one equity round; the number is equity rounds taken part in.
Related companies shared investors
Chai DiscoveryHealth · $600M in 2025–2026Shared: Dimension, DST GlobalWaymoRobotics · $16B in 2025–2026Shared: DST GlobalWhatnotConsumer · $1B in 2025–2026Shared: DST GlobalCREDFintech · $900M in 2025–2026Shared: DST GlobalOpenEvidenceHealth · $660M in 2025–2026Shared: DST GlobalHiggsfieldAI Apps · $530M in 2025–2026Shared: DST Global
Also in the Wilmington hub see on the globe
Figures in USD at the time of each round. See the methodology for how rounds are sourced and verified. Earendil Labs and its logo are trademarks of their owners, used here for identification only.